Ser213
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser213  -  NFAT3 (human)

Site Information
ASRFGLGsPLPsPRA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 953804

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 , 11 , 12 ) , mutation of modification site ( 13 )
Disease tissue studied:
breast cancer ( 3 , 7 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 7 ) , non-small cell lung cancer ( 7 ) , ovarian cancer ( 3 ) , pancreatic ductal adenocarcinoma ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 4 ) , breast ( 1 , 3 ) , BT-549 (breast cell) ( 7 ) , Calu 6 (pulmonary) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 8 ) , H2077 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1359 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 10 , 11 ) , Jurkat (T lymphocyte) ( 5 , 12 ) , K562 (erythroid) ( 11 ) , LCLC-103H (pulmonary) ( 7 ) , LOU-NH91 (squamous) ( 7 ) , MDA-MB-231 (breast cell) ( 7 ) , MEF (fibroblast) ( 13 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 7 ) , ovary ( 3 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Putative in vivo kinases:
JNK1 (mouse) ( 13 ) , JNK2 (mouse) ( 13 )
Kinases, in vitro:
JNK1 (human) ( 13 ) , JNK2 (human) ( 13 )
Treatments:
EGF ( 11 ) , ischemia ( 3 )

Downstream Regulation
Effects of modification on biological processes:
transcription, induced ( 13 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

5

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

6

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

7

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

8

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

9

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

10

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

11

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

12

Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

13

Yao K, et al. (2007) Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 induced cell transformation. Cancer Res 67, 8725-35
17875713   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.